Clinical Use of Curcumin in Depression: A Meta-Analysis

Published:February 21, 2017DOI:



      There is growing interest in the use of curcumin, a plant polyphenol with potent anti-inflammatory, anti-oxidant, and neuroprotective properties, as a novel antidepressant. Clinical trials have yielded conflicting conclusions pertaining to its effectiveness in depression. A meta-analysis of the topic, which has not been done until now, is therefore necessary to summarize current evidence and generate hypotheses for further research.


      Using the keywords [curcumin OR diferuloylmethane OR curcuminoid OR turmeric OR Indian saffron] AND [depression OR MDD OR suicide], a preliminary search on the PubMed, Ovid, Clinical Trials Register of the Cochrane Collaboration Depression, Anxiety and Neurosis Group (CCDANTR), and Cochrane Field for Complementary Medicine database yielded 2081 articles published in English between January 1, 1960, and August 1, 2016.


      Six clinical trials with a total of 377 patients were reviewed, comparing the use of curcumin to placebo. In patients with depression, the pooled standardized mean difference from baseline Hamilton Rating Scale for Depression scores (pooled standardized mean difference −0.344, 95% confidence interval −0.558 to −0.129; P = .002) support the significant clinical efficacy of curcumin in ameliorating depressive symptoms. Significant anti-anxiety effects were also reported in 3 of the trials. Notably, no adverse events were reported in any of the trials. Most trials had a generally low risk of bias, except for an open trial of curcumin and a single-blinded study.


      Because of the small number of studies available, a funnel plot or sensitivity analysis was not possible. Evidence on the long-term efficacy and safety of curcumin is also limited as the duration of all available studies ranged from 4 to 8 weeks.


      Curcumin appears to be safe, well-tolerated, and efficacious among depressed patients. More robust randomized controlled trials with larger sample sizes and follow-up studies carried out over a longer duration should be planned to ascertain its benefits.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Depression [Internet]. World Health Organization, 2016. Available at: Accessed November 25, 2016.

        • Scott J.
        • Dickey B.
        Global burden of depression: The intersection of culture and medicine.
        Br J Psychiatry. 2003; 183: 92-94
        • Chisholm D.
        • Diehr P.
        • Knapp M.
        • et al.
        Depression status, medical comorbidity and resource costs.
        Br J Psychiatry. 2003; 183: 121-131
        • Fava M.
        • Rush A.J.
        • Alpert J.E.
        • et al.
        Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR* D report.
        Am J Psychiatry. 2008; 165: 342-351
        • Trivedi M.H.
        • Fava M.
        • Wisniewski S.R.
        • et al.
        Medication augmentation after the failure of SSRIs for depression.
        N Engl J Med. 2006; 354: 1243-1252
        • Rush A.J.
        • Trivedi M.H.
        • Wisniewski S.R.
        • et al.
        Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR* D report.
        Am J Psychiatry. 2006; 163: 1905-1917
        • Tranter R.
        • O'Donovan C.
        • Chandarana P.
        • Kennedy S.
        Prevalence and outcome of partial remission in depression.
        J Psychiatry Neurosci. 2002; 27: 241-247
        • Corson T.W.
        • Crews C.M.
        Molecular understanding and modern application of traditional medicines: Triumphs and trials.
        Cell. 2007; 130: 769-774
        • Goel A.
        • Aggarwal B.B.
        Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.
        Nutr Cancer. 2010; 62: 919-930
        • Singh S.
        From exotic spice to modern drug?.
        Cell. 2007; 130: 765-798
        • Xu Y.
        • Ku B.S.
        • Yao H.Y.
        • et al.
        The effects of curcumin on depressive-like behaviors in mice.
        Eur J Pharmacol. 2005; 518: 40-46
        • Ak T.
        • Gülçin İ.
        Antioxidant and radical scavenging properties of curcumin.
        Chemico-Biol Interactions. 2008; 174: 27-37
        • Aggarwal B.
        • Harikumar K.
        Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.
        Int J Biochem Cell Biol. 2009; 41: 40-59
        • Dong S.
        • Zeng Q.
        • Mitchell E.
        • et al.
        Curcumin enhances neurogenesis and cognition in aged rats: Implications for transcriptional interactions related to growth and synaptic plasticity.
        PLoS One. 2012; 7: e31211
        • Xu Y.
        • Ku B.S.
        • Yao H.Y.
        • et al.
        Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats.
        Pharmacol Biochem Behav. 2005; 82: 200-206
        • Li Y.
        • Wang F.
        • Pan Y.
        • et al.
        Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats.
        Progr Neuropsychopharmacol Biol Psychiat. 2009; 33: 435-449
        • Panahi Y.
        • Badeli R.
        • Karami G.
        • Sahebkar A.
        Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder.
        Phytother Res. 2014; 29: 17-21
        • Esmaily H.
        • Sahebkar A.
        • Iranshahi M.
        • et al.
        An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial.
        Chin J Integr Med. 2015; 21: 332-338
        • Andrade C.
        A critical examination of studies on curcumin for depression.
        J Clin Psychiatry. 2014; 75: e1110-e1112
        • Jadad A.R.
        • Moore R.A.
        • Carroll D.
        • et al.
        Assessing the quality of reports of randomized clinical trials: Is blinding necessary?.
        Control Clin Trials. 1996; 17: 1-2
        • Higgins J.P.
        • Altman D.G.
        • Gøtzsche P.C.
        • et al.
        The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Bergman J.
        • Miodownik C.
        • Bersudsky Y.
        • et al.
        Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study.
        Clin Neuropharmacol. 2013; 36: 73-77
        • Lopresti A.L.
        • Maes M.
        • Maker G.L.
        • et al.
        Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study.
        J Affect Disord. 2014; 167: 368-375
        • Panahi Y.
        • Badeli R.
        • Karami G.R.
        • Sahebkar A.
        Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder.
        Phytother Res. 2015; 29: 17-21
        • Sanmukhani J.
        • Satodia V.
        • Trivedi J.
        • et al.
        Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial.
        Phytother Res. 2014; 28: 579-585
        • Yu J.J.
        • Pei L.B.
        • Zhang Y.
        • et al.
        Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study.
        J Clin Psychopharmacol. 2015; 35: 406-410
        • Kulkarni S.
        • Bhutani M.
        • Bishnoi M.
        Antidepressant activity of curcumin: Involvement of serotonin and dopamine system.
        Psychopharmacology. 2008; 201: 435-442
        • Bhutani M.K.
        • Bishnoi M.
        • Kulkarni S.K.
        Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes.
        Pharmacol Biochem Behav. 2009; 92: 39-43
        • Wang R.
        • Li Y.B.
        • Li Y.H.
        • et al.
        Curcumin protects against glutamate excitotoxicity in rat cerebral cortical neurons by increasing brain-derived neurotrophic factor level and activating TrkB.
        Brain Res. 2008; 1210: 84-91
        • Wong M.
        • Dong C.
        • Maestre-Mesa J.
        • Licinio J.
        Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response.
        Mol Psychiatry. 2008; 13: 800-812
        • Chan M.
        • Huang H.
        • Fenton M.
        • Fong D.
        In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties.
        Biochem Pharmacol. 1998; 55: 1955-1962
        • Siegel G.
        Basic Neurochemistry: Molecular, Cellular and Medical Aspects.
        1st ed. Elsevier, Philadelphia, PA2006
        • Maes M.
        • Kallaur A.
        • Lopes J.
        • et al.
        Immune-inflammatory and oxidative and nitrosative stress (IO and NS) pathways in depression and multiple sclerosis (MS): Shared IO and NS pathways but less hyper-acute neuro-inflammation explain the increased incidence of depression in MS.
        Neurol Psychiatry Brain Res. 2016; 22: 16-17
        • Coppen A.
        The biochemistry of affective disorders.
        Br J Psychiatry. 1967; 113: 1237-1264
        • Hatcher H.
        • Planalp R.
        • Cho J.
        • et al.
        Curcumin: From ancient medicine to current clinical trials.
        Cell Mol Life Sci. 2008; 65: 1631-1652
        • Gong Z.
        • Zhou J.
        • Li H.
        • et al.
        Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock.
        Mol Nutr Food Res. 2015; 59: 2132-2142
        • Zunszain P.
        • Hepgul N.
        • Pariante C.
        Inflammation and depression.
        Curr Top Behav Neurosci. 2013; 14: 135-151
        • Xu Y.
        • Ku B.
        • Tie L.
        • et al.
        Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB.
        Brain Res. 2006; 1122: 56-64
        • Kokmen E.
        • Beard C.
        • O'Brien P.
        • Kurland L.
        Epidemiology of dementia in Rochester, Minnesota.
        Mayo Clin Proc. 1996; 71: 275-282
        • Fava M.
        • Graves L.M.
        • Benazzi F.
        • et al.
        A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment.
        J Clin Psychiatry. 2006; 67: 1754-1759
        • Mendlewicz J.
        • Kriwin P.
        • Oswald P.
        • et al.
        Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study.
        Int Clin Psychopharmacol. 2006; 21: 227-231
        • Gaynes B.
        • Warden D.
        • Trivedi M.
        • et al.
        What Did STAR*D Teach Us? Results from a large-scale, practical, clinical trial for patients with depression.
        Psychiatr Serv. 2009; 60: 1439-1445
        • Ammon H.
        • Wahl M.
        Pharmacology of Curcuma longa.
        Planta Med. 1991; 57: 1-7
        • Yang F.
        • Lim G.P.
        • Begum A.N.
        • et al.
        Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
        J Biol Chem. 2005; 280: 5892-5901
        • Tsai Y.M.
        • Chien C.F.
        • Lin L.C.
        • Tsai T.H.
        Curcumin and its nano-formulation: The kinetics of tissue distribution and blood–brain barrier penetration.
        Int J Pharmaceut. 2011; 416: 331-338
        • Shoba G.
        • Joy D.
        • Joseph T.
        • et al.
        Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers.
        Planta Medica. 1998; 64: 353-356
        • Mythri R.B.
        • Jagatha B.
        • Pradhan N.
        • et al.
        Mitochondrial complex I inhibition in Parkinson's disease: How can curcumin protect mitochondria?.
        Antioxid Redox Signal. 2007; 9: 399-408
        • Chainani-Wu N.
        Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa).
        J Altern Complement Med. 2003; 9: 161-168
        • Blier P.
        • Keller M.B.
        • Pollack M.H.
        • et al.
        Preventing recurrent depression: Long-term treatment for major depressive disorder.
        J Clin Psychiatry. 2007; 68: e06